A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

The upgrade from 'reduce' to 'buy' is based on a more optimistic view of the company's custom synthesis segment.

USA: A new study published in the Journal of Diabetes and Its Complications suggests that tirzepatide, a novel dual ...

HSBC Global Research has upgraded Divi's Laboratories Ltd. from a ‘reduce’ to a ‘buy’ rating, citing strong growth potential ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Oh My Meds LogoOh My Meds expands nationwide with personalized peptide therapies, offering virtual care and fast home ...

Morgan Stanley had reiterated its "overweight" recommendation on Divi's Laboratories, with a price target of ₹7,185 apiece.

GIRLS actress Jenny Mollen has revealed she was rushed to hospital following a terrifying reaction to a fat-dissolving ...